We report an initial clinical experience to evaluate the safety and efficacy of outpatient prostatic ablation for the treatment of symptomatic benign prostatic hyperplasia (BPH) using local anesthesia (OPAL 1 ) with radio-frequency energy and intraprostatic absolute ethanol injection (EI). Twenty-three patients were treated with OPAL 1 and five patients were treated with EI. Pre-operative data for all patients included international prostate symptom score (IPSS), quality of life score (QL), maximum flow rate (Q max ), and post void residual determination. Prostate specific antigen (PSA) and transrectal ultrasound prostate volume determination were also done for EI patients. Needle deployment into the prostate was carried out at the 2, 4, 8 and 10 o'clock positions for lateral lobe hyperplasia and the 6 o'clock position for middle lobe hyperplasia. IPSS, QL, Q max and post void residual data were collected at 1, 3, 6 and 12 months post procedure. Both procedures resulted in statistically significant reductions of IPSS and QL. Trends towards improvement were seen both for Q max and post void residual, with Q max significantly improved after OPAL 1 . Among EI patients, the prostate volume was reduced at 6 months post treatment to 37.2 AE 17.9 g from 53.0 AE 19.0 g (P ¼ 0.03) preoperatively. OPAL 1 was safe but suffered from a high re-treatment rate. EI demonstrated encouraging results with regards to safety, symptom improvement and prostate volume reduction.
Introduction
Minimally invasive treatments of symptomatic benign prostatic hyperplasia (BPH) have been adopted by many centers for treatment of patients who fail pharmacological manipulation and cannot or do not want to undergo transurethral resection. Numerous different modalities have been developed with most delivering energy of some form across the electromagnetic spectrum to prostatic tissue. The premise of these therapies is in situ ablation of prostatic tissue. To date, none have gained widespread acceptance, especially across continental boundaries. Many of the currently available therapies require large capital equipment investments with high per case disposable costs. 1 This led us to first investigate the use of outpatient tissue ablation under local anesthesia (OPAL 1 ) as a novel and potentially less expensive, minimally invasive treatment for BPH.
The OPAL 1 needle (Figure 1 -Prosurg, Santa Barbara) uses a hollow-core single needle deployment system. The needle is deployed distal to the cystoscope lens under direct vision, allowing for both lateral and middle lobe ablation. Radio-frequency (RF) energy, the same type of energy as the more widely used transurethral needle ablation (TUNA 1 ) procedure, is delivered to create zones of heat induced coagulative necrosis. This procedure utilizes a probe that is introduced into the prostate using any 19 -22 French cystoscope sheath ( Figure 1 ). Any standard diathermy unit can be used and only tissue impedance is actively monitored during the treatment. These factors serve to greatly reduce the overall costs of the procedure.
After completion of several initial ex vivo experiments evaluating the efficacy of tissue ablation, 2 a clinical research protocol was submitted and approved by the University of Vermont Institutional Review Board (UVM IRB).
In follow-up to our experience with the OPAL 1 procedure, with the premise to develop a more efficient and effective manner to ablate tissue in situ, we investigated chemoablation with ethanol, the agent with the largest experience for human tissue ablation to date. 3 The first publication examining ethanol ablation used a canine model with a transperineal injection technique. 4 Leakage outside the prostate was documented with both bladder and external sphincter necrosis seen. Our hypothesis began with the concept that if the ethanol is delivered using a transurethral route, it will avert prostatic capsule disruption and no leakage will occur. Canine studies were performed at our institution, documenting effective and rapid tissue ablation at the level of the prostate with transurethral absolute ethanol injection. 3 Systemic absorption was minimal and the prostatic capsule was found to act as a relative barrier to ethanol diffusion with no extra prostatic leakage seen.
A follow-up limited clinical trial, involving five patients, examining the safety and efficacy of transurethral prostatic ablation with ethanol was subsequently submitted and approved by the UVM IRB. Subsequently, the Food and Drug Administration regulation prevented further patient study in the USA without a formal New Drug Application. A multi-center trial is now ongoing in the USA.
Materials and methods
Patient inclusion and exclusion criteria are outlined in Table 1 with a 1-month washout period observed for those patients on a-blockers and 3 months for a 5a-reductase inhibitor. Operative patient evaluation criteria are outlined in Tables 2 and 3 for OPAL 1 and EI respectively. Informed consent was obtained from all patients as per the guidelines set forth by the UVM IRB.
OPAL 1 procedure
From October 1997 to May 1998, 23 patients underwent the OPAL 1 procedure. All procedures were performed in the operating room by a single surgeon (MKP), using transurethral xylocaine jelly and conscious i.v. sedation. Prostatic ablation was carried out using a 19 French rigid cystoscope and a 30 lens using the OPAL 1 needle. Deployments were made approximately 1 cm distal to the bladder neck at the 2, 4, 8 and 10 o'clock positions for lateral lobe hyperplasia and at the 6 o'clock position for middle lobe hyperplasia where present. Depth of deployment was 1.0 cm. In those patients with a prostatic urethral length of greater than 2 cm, two separate planes of treatment were performed with the second approximately 0.5 -1.0 cm distal from the first. As specified by the manufacturer and confirmed in ex vivo evaluation as 
appropriate, 12 W of pure 'cutting' radio frequency energy were used. The total procedure time was measured in all cases. All patients were discharged home after the procedure with an indwelling Foley catheter left to straight drainage. Peri-operative antibiotics for seven days, an anticholinergic and a weak oral narcotic were prescribed in all cases. All catheters were removed one week postoperatively with subsequent objective postoperative evaluation criteria measured as outlined in Table 2 .
Ethanol ablation
From February to August 1999, five patients were treated under spinal anesthesia, in the operating room, by a single surgeon (MKP). With the patient in lithotomy position, urethrocystoscopy was performed using a 19 French rigid cystoscope and a 30 lens. Using the same cystoscopic equipment, and the height and width of the prostate confirmed > 3.0 cm on TRUS, the axially deflecting hollow core OPAL 1 needle was deployed 1.0 cm into the prostatic tissue under direct vision and ethanol injection was performed in combination with continuous cystoscopic saline irrigation. The bladder was drained completely after each injection. Needle deployment was carried out at the 2, 4, 8 and 10 o'clock positions for lateral lobe hyperplasia and the 6 o'clock position for middle lobe hyperplasia. A target volume of 2 ml was established for each injection. Injections were terminated when ethanol backflow into the urethra was observed. The first plane of injection was 1.0 cm distal from the bladder neck with a second plane 0.5 -1.0 cm distal to this if the prostatic urethral length exceeded 2.0 cm.
At the termination of the procedure, blood alcohol levels were determined immediately and 4 h post procedure. All patients were kept in the recovery room for a total of 4 -6 h postoperatively and discharged home with an indwelling Foley catheter left to straight drainage. Peri-operative antibiotics were continued until catheter removal one week postoperatively. All patients were prescribed an anticholinergic and a weak narcotic. Subsequently, objective postoperative evaluation criteria were determined as outlined in Table 3 including repeat TRUS and PSA at 6 months post procedure.
Statistical analysis
The mean values for the parameters measured prior to and 12 months following treatment were compared using a two-sided paired sample t-test. In addition, postoperative trends in parameters were examined using repeated measures analysis of variance with linear contrast. Due to the small sample size, adjustments were not made for multiple comparisons. A P-value of less than 0.05 was considered statistically significant.
Results

OPAL 1 procedure
Mean patient age was 68.9 y (58 -77 y). The mean procedure time was 46 min (28 -75 minutes) and comprised the time required for each ablation site and the number of planes of treatment. Single site ablation time ranged from 45 seconds to 5.0 min. Six-month follow-up was completed in 20 patients. Twelve-month evaluation data were obtained for 19 patients with four patients lost to follow-up.
Overall, at 12 months post procedure, statistically significant improvements were seen in international prostate symptom score (IPSS), quality of life score (QL), and maximum flow rate (Q max ). No significant change in post void residual was evidenced. The results are summarized in Table 2 . Three patients suffered from urinary retention after catheter removal, all resolving within 2 weeks or less.
Of the 11 patients not requiring further treatment for symptom improvement at 12 months post procedure, none have gone on to require further treatment to a mean follow-up time of 40 months.
Twelve months after undergoing the OPAL 1 procedure, eight patients were not satisfied with their symptomatic improvement, required further treatment and were considered non-responders. Three of these patients who originally did not respond to pharmacologic therapy were successfully restarted on an a-blocker and four patients decided to undergo a transurethral resection of the prostate (TURP). The last non-responder, with severe chronic obstructive pulmonary disease that precluded transurethral resection, required chronic catheterization for symptom relief.
No significant peri-operative complications occurred and no complaints of erectile dysfunction or urinary incontinence were reported.
Responders and non-responders were compared for their relative levels of irritative and obstructive symptoms as well as the number of planes of treatment (Table 4 ). The results suggest that better outcomes were obtained for prostates with a shorter urethral length, requiring only one plane of treatment. However, this difference was not found to be statistically significantly different. No statistically significant difference was seen between the two groups with regards to their respective levels of obstructive versus irritative symptoms. 
Ethanol ablation
Treated patient ages ranged from 60 to 79 y of age (mean 71.9 y). Total operative time ranged from 10 to 30 min (mean 17.4 min) and total volumes of ethanol injected were 10 -16 ml (mean 14.3 ml -27% of prostate volume).
No intra-operative complications occurred and blood ethanol concentrations immediately following and 4 h after the procedure were undetectable in all patients. All the patients had slight hematuria post procedure that cleared spontaneously within 48 h. Upon catheter removal, four patients voided without difficulty. One patient went into acute retention and had to be recatheterized for a further week. He was able to void without difficulty thereafter. One patient had increased irritative voiding for 1 month after the procedure that resolved spontaneously without further treatment.
Results of the subjective and objective assessments are outlined in Table 3 . Both symptom and quality of life scores were improved throughout the follow-up period with changes found to be statistically significant at 12 months.
Peak uroflow rates increased slightly from baseline in all five patients, however, at 12 months, improvements were not statistically significant. No improvement was seen in the post void residual overall. Reductions in serum PSA were evidenced in all patients. The mean reduction of prostate volume was 30% at 6 months postoperatively (53.0 cc to 37.2 cc), reaching statistical significance.
To date, no patients have required further treatment including the one patient who failed to notice subjective improvement. No other complications have occurred postoperatively and no complaints of incontinence, erectile dysfunction or retrograde ejaculation have been reported.
Discussion
Several different types of energy are presently used to ablate prostatic tissue creating thermal damage with resultant coagulative necrosis. RF energy has shown much potential as patients can be treated using local anesthesia with minimal sedation on an outpatient basis and requires less initial capital equipment expense as compared to other energy sources. Different delivery systems using RF energy have been used including the use of a low-cost straight needle-electrode, with results showing subjective patient improvement. 5, 6 The most commonly performed procedure using RF energy is TUNA. Reported results regarding its efficacy in relieving symptoms of prostatism have varied, with the most promising comparing favorably to the gold standard, transurethral prostate resection. 7 This therapy requires a much larger capital equipment investment and has a higher disposable needle cost as compared to other methods.
OPAL 1 , as previously described, uses a single needle with only tissue impedance continuously monitored. It requires a much lower initial capital equipment investment and significantly reduced disposable cost per case. The OPAL 1 tissue ablation probe creates zones of heat induced coagulative necrosis through RF energy delivery. The active needle electrode responsible for RF energy delivery is a 20 G hollow-core needle, providing a very small surface area for tissue contact. It passively deflects in a plane axial to the cystoscope sheath and, when fully deployed, the needle tip is perpendicular to the cystoscope (Figure 1) . The probe connects to any standard RF energy generator. RF energy is delivered through the active electrode (single needle probe) with subsequent collection by the passive electrode (grounding pad) with a much larger surface area. An impedence monitor that is connected in series with both the patient and RF generator records tissue impedence (resistance) continuously. When impedence has reached a plateau (infinity), demonstrating that tissue desiccation is present, no further current can be delivered and the treatment is discontinued. The size of the lesion created will therefore have reached its maximum. The length of each treatment is determined by the total duration of continuous current flow as measured by continuous impedence monitoring. Further, the OPAL 1 needle positioning distal to the cystoscopic lens allows for visual control of deployment and therefore more secure treatment of median lobe hyperplasia where present. This makes the procedure more amenable to all prostatic anatomy, and increased urologist acceptance is likely given the visual control offered.
In ex vivo experiments, the OPAL 1 probe created reproducible zones of tissue destruction using the manufacturers recommended settings. 2 In this non-randomized study of outpatient prostate ablation under local anesthesia, we used the same energy level of 12 W. The procedure proved both simple and safe to perform with no serious morbidity noted. All cases had minimal anesthetic requirements and were performed on an outpatient basis. Although the overall results appear to show significant improvement among this initial group of patients, the OPAL 1 procedure proved to be clearly inferior to many other BPH therapies with regards to treatment failures with no identifiable preoperative predictive criteria for treatment success.
A likely hypothesis lies in the fact that RF energy tissue ablation is not efficient enough to ablate equal volumes of tissue as compared to that resected with TURP. RF energy heats tissues to 80 -100 C, thereby resulting in zones of coagulative necrosis. 8 RF energy heats tissue by resistive (ohmic) heating with current flow decreasing rapidly as a function of 1/r 2 (radius). As a result, only the tissue in contact with the electrode is heated directly. Deeper tissue heating occurs as a result of conduction. Both current flow and conduction are directly related to the presence of electrolyte in the tissue. As the tissue temperature approaches 100 C, tissue desiccation ensues with a resultant sharp increase in impedence. This interrupts current flow, preventing further conduction of heat. The OPAL 1 system, in being cost effective, may also represent an oversimplification that may ultimately limit efficacy. The delivery of a steady current to the prostate with only impedence monitored and no thermistor measurement of prostatic tissue temperature will not allow for possible current adjustments to be made to reduce desiccation, as in the TUNA 1 procedure. The mean procedure time in this study, 46 min, was quite long, especially considering the need for rigid cystoscopy for needle deployment.
Other attempts to ameliorate RF energy ablative efficacy have focused on reducing tissue desiccation. Hoey et al 9,10 described a technique using interstitial infusion of electrolyte solution during RF energy treatment via a transperineal approach in a canine animal model, allowing for more current to flow deeper into the tissue as a result of reduced tissue desiccation, with larger lesions subsequently created. Treatment times are also increased, however. The combination of RF energy delivery with concomitant infusion of an electrolyte solution has also been described and referred to as the 'virtual electrode' with clinical trials ongoing. 11 With the disappointing results using RF ablation, other ways to ablate tissue were considered. Given the hollow core feature of the OPAL 1 needle, chemoablation was considered. Chemoablation of the prostate is not a new concept and the earliest reports of its use date back to the early twentieth century. The first published report was in 1966 by Talwar and Pande 4 using a 'phenol' solution. Follow-up attempts using a transperineal route of injection had variable results and demonstrated extra capsular leakage of the injected solution. 12 -17 This was further demonstrated by Littrup et al 18 in the first published use of ethanol, the most widely used chemoablative agent today for prostatic tissue. These reports also demonstrated the feasibility of prostatic chemoablation.
We confirmed the hypothesis that the prostatic pseudocapsule may act as a relative barrier to ethanol diffusion to extraprostatic tissues in canine studies using a transurethral injection route. 18 Ablative effects were confined to the prostatic tissue with no injury to the striated urethral sphincter and peri-prostatic tissues. Minimal systemic absorption of ethanol was evidenced and further reported with much larger volumes of injection in humans by Livraghi et al. 19 Our initial experience with transurethral ethanol ablation of the prostate has produced very promising results. The procedure was relatively simple, short and without any major complications. All patients were treated with regional anesthesia with low injection to prostate volume ratio to minimize any potential difficulties for this first group of patients. Potential for improvement of objective criteria, especially peak flow rates may be therefore underestimated. Further, our canine studies have shown a correlation between injected volume and volume of prostate ablated. The reduction in gland volume and PSA are felt to be indicators of the promising nature of this treatment for relief of outflow obstruction.
The first published report of transurethral ethanol ablation of the prostate in humans was by Goya et al. 20 Small volumes of ethanol (12% of prostate volume) were injected tangentially using varying patterns of injection with a straight needle. Promising results were reported, however, with no reduction in gland volume, which may be related to the more superficial injection technique and resultant injection volume limitation.
No further ethanol injection procedures have been performed on patients at the UVM as a result of a meeting in October of 1999 with the FDA whereby it was learned that ethanol use in the prostate would be considered a new drug indication and would require a formal IND submission before approval. A multicenter phase I/II study (IND 61 337) is now ongoing in the USA.
